Abstract
Background and Objective: Asenapine is an atypical antipsychotic approved by US Food and Drug Administration in 2009 and by European Medicines Agency in 2010 for Schizophrenia and Bipolar Disorder treatment. Currently, many studies have been developed in an attempt to clarify and minimize the risks related to the use of psychotropic during pre/postnatal period on patients with a history of mental disorders.
Conclusion: The aim of this study was to test the impact of pre and/or postnatal exposition to asenapine on mice offspring behavior. Four groups of animals, previously treated with a dosage equivalent to 50% of the bioavailability obtained with a 20 mg daily use for human treatment, were exposed to the Open Field and Elevated plus Maze test. Only the group exposed to asenapine during both pre and postnatal periods showed response difference in the Elevated Plus Maze test, which was restricted to urination. However, our data suggest that the administration of asenapine does not induce significant anxiety-like behaviors in mice.
Keywords: Antipsychotic, schizophrenia, bipolar disorder, behaviour, anxiety, stress, open field, elevated plus maze.
CNS & Neurological Disorders - Drug Targets
Title:Systemic Administration of Antipsychotic Asenapine Pre or Postnatal does not Induce Anxiety-like Behaviors in Mice
Volume: 16 Issue: 10
Author(s): Thais Barbosa de Souza, Daniela Miranda Farias, Rozimeri Fatima Coletti, Maria Silvia Oliveira, Carolina Gomes Carrilho, Jorge Aparecido de Barros, Susana Elisa Moreno, Eric Murillo-Rodriguez, Sergio Machado and Andre Barciela Veras*
Affiliation:
- Intercontinental Neuroscience Research Group, Campo Grande,Brazil
Keywords: Antipsychotic, schizophrenia, bipolar disorder, behaviour, anxiety, stress, open field, elevated plus maze.
Abstract: Background and Objective: Asenapine is an atypical antipsychotic approved by US Food and Drug Administration in 2009 and by European Medicines Agency in 2010 for Schizophrenia and Bipolar Disorder treatment. Currently, many studies have been developed in an attempt to clarify and minimize the risks related to the use of psychotropic during pre/postnatal period on patients with a history of mental disorders.
Conclusion: The aim of this study was to test the impact of pre and/or postnatal exposition to asenapine on mice offspring behavior. Four groups of animals, previously treated with a dosage equivalent to 50% of the bioavailability obtained with a 20 mg daily use for human treatment, were exposed to the Open Field and Elevated plus Maze test. Only the group exposed to asenapine during both pre and postnatal periods showed response difference in the Elevated Plus Maze test, which was restricted to urination. However, our data suggest that the administration of asenapine does not induce significant anxiety-like behaviors in mice.
Export Options
About this article
Cite this article as:
de Souza Barbosa Thais , Farias Miranda Daniela , Coletti Fatima Rozimeri , Oliveira Silvia Maria , Carrilho Gomes Carolina, de Barros Aparecido Jorge , Moreno Elisa Susana, Murillo-Rodriguez Eric , Machado Sergio and Veras Barciela Andre *, Systemic Administration of Antipsychotic Asenapine Pre or Postnatal does not Induce Anxiety-like Behaviors in Mice, CNS & Neurological Disorders - Drug Targets 2017; 16 (10) . https://dx.doi.org/10.2174/1871527317666171213162403
DOI https://dx.doi.org/10.2174/1871527317666171213162403 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Application of Induced Pluripotent Stem Cells in Cell Replacement Therapy for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Substance P and Alzheimer’s Disease: Emerging Novel Roles
Current Alzheimer Research Organelle Stress Sensors and Cell Death Mechanisms in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets The Role of α7 Nicotinic Acetylcholine Receptors and α7-Specific Antibodies in Neuroinflammation Related to Alzheimer Disease
Current Pharmaceutical Design Transgenic Mice as a Model for Alzheimers Disease
Current Alzheimer Research Editorial (Thematic Issue: Small Molecule Therapeutics for Alzheimer’s Disease)
Current Alzheimer Research Oxidative Stress Mechanisms and Potential Therapeutic Modalities in Alzheimer Disease
Medicinal Chemistry Reviews - Online (Discontinued) Editorial [Continue the Great Journey of Success!]
Current Molecular Medicine Pre-Dementia Diagnosis of Alzheimers Disease: Translating Clinicobiologic Research into Practice
Current Psychiatry Reviews Discovering New Treatments for Alzheimer's Disease by Repurposing Approved Medications
Current Topics in Medicinal Chemistry Neurotrophic Factors as a Protective Strategy in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective
Current Drug Metabolism Resveratrol, A Neuroprotective Supplement for Alzheimer's Disease
Current Pharmaceutical Design Motor and Non-Motor Features of Parkinson’s Disease – A Review of Clinical and Experimental Studies
CNS & Neurological Disorders - Drug Targets Copy Number Variants in Neurological Disorder
Current Genomics Berberine: A Plant-derived Alkaloid with Therapeutic Potential to Combat Alzheimer’s disease
Central Nervous System Agents in Medicinal Chemistry Monoamine Oxidase B Inhibitors in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Receptor-Interacting Protein Kinase 1 (RIPK1) as a Potential Therapeutic Target: An Overview of Its Possible Role in the Pathogenesis of Alzheimer's Disease
Current Alzheimer Research A New Drug Candidate (GEMSP) for Multiple Sclerosis
Current Medicinal Chemistry Meet Our Associate Editor
Current Molecular Medicine